10 nations control 80% of all global clinical trials.
Top 10 Share
80%
US Share
Dominant
Global South
<5%
Model
Hegemony index
Key Finding
The United States alone accounted for 47% of the combined four-region total, maintaining absolute dominance in drug discovery and regulatory approval.
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Immunotherapy: AF 92 vs US 3,803 (41.3x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Health innovation operates as an entrenched global monopoly. Ten high-income nations control 80% of all clinical research volume, leaving the entire Global South marginalised. The US alone accounts for ~38% of global trial activity. Africa and South America together share less than 5%. This is not a market — it is a monopoly.
The Evidence 150 words · target 156
In geopolitical analysis, does the distribution of clinical trials across sovereign nations indicate a monopolistic concentration of scientific infrastructure at the planetary scale? This audit compared total trial volumes across major regions: United States (190,644), Europe (142,126), China (49,763), and Africa (23,873) using ClinicalTrials.gov data through March 2026. The top ten research nations controlled an estimated eighty percent of the global trial volume, while the entire Global South including Africa and South America shared less than five percent. The United States alone accounted for 47% of the combined four-region total, maintaining absolute dominance in drug discovery and regulatory approval. Africa's 5.9% share meant that 1.4 billion people were represented by a fraction of the evidence base guiding global medical practice. These findings demonstrate that health innovation operates as an entrenched monopoly rather than a distributed enterprise. Interpretation is limited by the exclusion of national registries which may inflate US dominance.
Sentence Structure
Question
In geopolitical analysis, does the distribution of clinical trials across sovereign nations indicate a monopolistic concentration of scientific infrastructure at the planetary scale?
Dataset
This audit compared total trial volumes across major regions: United States (190,644), Europe (142,126), China (49,763), and Africa (23,873) using ClinicalTrials.gov data through March 2026.
Method
The top ten research nations controlled an estimated eighty percent of the global trial volume, while the entire Global South including Africa and South America shared less than five percent.
Primary Result
The United States alone accounted for 47% of the combined four-region total, maintaining absolute dominance in drug discovery and regulatory approval.
Robustness
Africa's 5.9% share meant that 1.4 billion people were represented by a fraction of the evidence base guiding global medical practice.
Interpretation
These findings demonstrate that health innovation operates as an entrenched monopoly rather than a distributed enterprise.
Boundary
Interpretation is limited by the exclusion of national registries which may inflate US dominance.